Ocata Therapeutics Inc fka OCAT

[rocky301]

It is no secret that Jules Stein was under consideration from January PR. If Jules was the lead clinic that was suppose to have an approval meeting last week, and did approve IRB, then we will know well before May. Once IRB approval is in and info is sent to clinicaltrials.gov, it still takes 2-5 days for PRS to review/process and publish. I am not saying Jules is the "lead clinic", we will know WHO when published. If I had to guess, I would say author posted premature info. In order for a trial TO BE conducted at Jules, IRB approval is needed. All clinical sites involved with trials will need IRB approval.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=61561497

(January PR for dry AMD)
The Phase I/II trial will be a prospective, open-label study that is designed to determine the safety and tolerability of the RPE cells following sub-retinal transplantation into patients with Dry AMD. Twelve patients will be enrolled in the study at multiple clinical sites. Sites currently under consideration are the Jules Stein Eye Institute at UCLA, and the Ophthalmology Department at Stanford University School of Medicine. Additional sites may be considered.